Abstract
The Cyclin-Dependent Kinases (CDKs) and their cyclin partners are key regulators of the cell cycle. These kinases are closely related to oncogenesis and have been proved to be attractive targets for designing novel anticancer agents. The CDK inhibitors can effectively suppress the excessive proliferation of tumor cells by inducing cell cycle arrest. In recent years, a large number of CDK inhibitors have entered pre-clinical and/or clinical trials. Among these compounds, the selective CDK4/6 inhibitor Palbociclib has been approved by FDA for breast cancer treatment. Moreover, Palbociclib demonstrated promising antitumor potential as monotherapy or combined therapy in numerous clinical trials. Herein, we provide a brief review focused on the recent progress of clinical studies about Palbociclib.
Keywords: Cyclin-Dependent Kinases (CDKs), palbociclib, monotherapy, combined therapy, anti-cancer, cell cycle arrest.
Anti-Cancer Agents in Medicinal Chemistry
Title:Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer
Volume: 18 Issue: 9
Author(s): Fengquan Chen, Chunxi Liu, Jian Zhang, Wenfang Xu*Yingjie Zhang*
Affiliation:
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012 Ji'nan, Shandong,China
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012 Ji'nan, Shandong,China
Keywords: Cyclin-Dependent Kinases (CDKs), palbociclib, monotherapy, combined therapy, anti-cancer, cell cycle arrest.
Abstract: The Cyclin-Dependent Kinases (CDKs) and their cyclin partners are key regulators of the cell cycle. These kinases are closely related to oncogenesis and have been proved to be attractive targets for designing novel anticancer agents. The CDK inhibitors can effectively suppress the excessive proliferation of tumor cells by inducing cell cycle arrest. In recent years, a large number of CDK inhibitors have entered pre-clinical and/or clinical trials. Among these compounds, the selective CDK4/6 inhibitor Palbociclib has been approved by FDA for breast cancer treatment. Moreover, Palbociclib demonstrated promising antitumor potential as monotherapy or combined therapy in numerous clinical trials. Herein, we provide a brief review focused on the recent progress of clinical studies about Palbociclib.
Export Options
About this article
Cite this article as:
Chen Fengquan , Liu Chunxi , Zhang Jian , Xu Wenfang *, Zhang Yingjie*, Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer, Anti-Cancer Agents in Medicinal Chemistry 2018; 18 (9) . https://dx.doi.org/10.2174/1871521409666170412123500
DOI https://dx.doi.org/10.2174/1871521409666170412123500 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Adsorption of Antifungal Drugs Inside Pristine and Functionalized Fullerenes and Nanotubes: DFT Investigation
Current Computer-Aided Drug Design Editorial (Thematic Issue: “Cell-penetrating Peptides and Drug Delivery”)
Current Pharmaceutical Biotechnology Regulation of Hypoxia-inducible Factor-1α and Vascular Endothelial Growth Factor Signaling by Plant Flavonoids
Mini-Reviews in Medicinal Chemistry RNAi in Clinical Studies
Current Medicinal Chemistry Cdc20: A Potential Novel Therapeutic Target for Cancer Treatment
Current Pharmaceutical Design Array-Based Approaches for the Identification of Epigenetic Silenced Tumor Suppressor Genes
Current Genomics Mucosal Healing in Crohn’s Disease: Relevance for Clinical Outcomes
Current Drug Targets Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Systemic Sclerosis: Clinical Manifestations
Current Rheumatology Reviews Nitroimidazole Radiopharmaceuticals in Hypoxia: Part II Cytotoxicity and Radiosensitization Applications
Current Radiopharmaceuticals Preventive and Therapeutic Role of Muscle Contraction Against Chronic Diseases
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Medical Imaging Nano Drug Delivery in Treatment of Oral Cancer, A Review of the Literature
Current Drug Targets Synthesis and Screening of N-Alkyl Hydroxamates for Inhibition of Cancer Cell Proliferation
Combinatorial Chemistry & High Throughput Screening Synthesis of [<sup>64</sup>Cu]Cu-NOTA-Bn-GE11 for PET Imaging of EGFR-Rich Tumors
Current Radiopharmaceuticals Current Technological Development of Antibody Therapeutics
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Patent Selections
Current Biomarkers (Discontinued) Mitochondrial Drug Targets in Cell Death and Cancer
Current Pharmaceutical Design Anti-Angiogenic Therapies for Children with Cancer
Current Cancer Drug Targets